Breast Cancer Now media statements
We respond to 'The projected impact of the COVID-19 lockdown on breast cancer deaths in England due to the cessation of population screening: a national estimation’
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to NHS England breast cancer waiting times: December 2021
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said:
Responding to new research that pembrolizumab cuts the risk of triple negative breast cancer returning by 37%
New research findings published in the New England Journal of Medicine found that pembrolizumab, if given in combination with chemo before s...
We respond to House of Commons library analysis revealing record numbers of women facing delays to see an NHS cancer specialist
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to Professor Gilbert’s talk at UK Interdisciplinary Breast Cancer Symposium, surrounding ‘Personalised breast cancer screening’
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, who hosted the UK Interdisciplinary Breast Cancer Symp...
Responding to a new AI tool being tested to establish HER2 status in breast cancer
Dr Kotryna Temcinaite, Senior Research Communications Manager at Breast Cancer Now, said:
We welcome the SMC’s approval of two new treatments for use on the NHS in Scotland- trastuzumab deruxtecan (Enhertu) and tucatinib (Tukysa) in combination with trastuzumab and capecitabine
The Scottish Medicines Consortium (SMC) has today announced its decision to recommend two new treatments – trastuzumab deruxtecan (Enhertu) ...
We respond to NHS England breast cancer waiting times: November 2021
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to a new study showing how some cancer cells are able to resist PARP inhibitor drugs
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to recent announcements around the COVID-19 booster jabs roll-out and share our concerns around potential disruption to breast cancer services caused by Omicron
Baroness Delyth Morgan, Chief Executive at Breast Cancer Now, said:
We respond to a new report from The Institute of Cancer Research, London, into cancer clinical trials
Dr Simon Vincent, Director of Research, Support and Influencing at Breast Cancer Now, said:
We respond to Macmillan Cancer Support's warning that "almost 50,000 people are still missing a cancer diagnosis in the UK"
Mia Rosenblatt, Associate Director of Policy, Evidence and Influencing at Breast Cancer Now, said: